ANAVEX LIFE SCIENCES CORP. (AVXL) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -17.37M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 5.93M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-17.37M | (m) | (m) | (m) | $5.93M | (m) |
| 2026-03-31 | $-38.57M | (m) | (m) | $26.10M | $12.47M | (m) |
| 2025-12-31 | $-44.60M | (m) | (m) | $31.80M | $12.80M | (m) |
| 2025-09-30 | $-51.41M | (m) | (m) | $37.59M | $13.82M | (m) |
| 2025-06-30 | $-54.84M | (m) | (m) | $41.91M | (m) | (m) |
| 2025-03-31 | $-54.98M | (m) | (m) | $43.76M | (m) | (m) |
| 2024-12-31 | $-55.09M | (m) | (m) | $43.60M | (m) | (m) |
| 2024-09-30 | $-52.88M | (m) | (m) | $41.84M | (m) | (m) |
| 2024-06-30 | $-51.19M | (m) | (m) | $40.34M | (m) | (m) |
| 2024-03-31 | $-49.99M | (m) | (m) | $38.76M | (m) | (m) |
| 2023-12-31 | $-51.66M | (m) | (m) | $40.33M | (m) | (m) |
| 2023-09-30 | $-55.76M | (m) | (m) | $43.72M | (m) | (m) |
| 2023-06-30 | $-58.39M | (m) | (m) | $45.04M | (m) | (m) |
| 2023-03-31 | $-57.32M | (m) | (m) | $44.03M | (m) | (m) |
| 2022-12-31 | $-54.65M | (m) | (m) | $41.33M | (m) | (m) |
| 2022-09-30 | $-50.99M | (m) | (m) | $37.92M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $35.91M | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $35.60M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $33.71M | (m) | (m) |
| 2021-09-30 | $-42.00M | (m) | (m) | $32.98M | (m) | (m) |
| 2020-09-30 | $-31.09M | (m) | (m) | $25.23M | (m) | (m) |
| 2015-06-30 | $-3.78M | (m) | (m) | $1.87M | (m) | (m) |
| 2015-03-31 | $-3.27M | (m) | (m) | $1.33M | (m) | (m) |
| 2014-12-31 | $-3.43M | (m) | (m) | $1.05M | (m) | (m) |
| 2014-09-30 | $-2.97M | (m) | (m) | $732.39K | (m) | (m) |
| 2014-06-30 | $-3.80M | (m) | (m) | $485.61K | (m) | (m) |
| 2014-03-31 | $-2.93M | (m) | (m) | $259.62K | (m) | (m) |
| 2013-12-31 | $-2.03M | (m) | (m) | $142.02K | (m) | (m) |
| 2013-09-30 | $-2.14M | (m) | (m) | $263.85K | (m) | (m) |
| 2013-06-30 | $-1.31M | (m) | (m) | $279.54K | (m) | (m) |
| 2013-03-31 | $-1.88M | (m) | (m) | $634.48K | (m) | (m) |
| 2012-12-31 | $-2.55M | (m) | (m) | $1.06M | (m) | (m) |
| 2012-09-30 | $-4.32M | (m) | (m) | $2.65M | (m) | (m) |
| 2012-06-30 | $-4.91M | (m) | (m) | $3.13M | (m) | (m) |
| 2012-03-31 | $-5.84M | (m) | (m) | $3.52M | (m) | (m) |
| 2011-12-31 | $-7.00M | (m) | (m) | $3.82M | (m) | (m) |
| 2011-09-30 | $-6.18M | (m) | (m) | $2.60M | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $-5.65M | (m) | (m) | $2.73M | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |